Show simple item record

dc.contributor.authorGirotti, Maria Romina
dc.contributor.authorMarais, Richard
dc.date.accessioned2013-06-14T15:17:54Z
dc.date.available2013-06-14T15:17:54Z
dc.date.issued2013-05
dc.identifier.citationDeja Vu: EGF Receptors Drive Resistance to BRAF Inhibitors. 2013, 3 (5):487-90 Cancer Discoven_GB
dc.identifier.issn2159-8290
dc.identifier.pmid23658295
dc.identifier.doi10.1158/2159-8290.CD-13-0131
dc.identifier.urihttp://hdl.handle.net/10541/293993
dc.description.abstractSummary: The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation. Cancer Discov; 3(5); 487-90. ©2013 AACR.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer discoveryen_GB
dc.titleDeja Vu: EGF Receptors Drive Resistance to BRAF Inhibitors.en
dc.typeArticleen
dc.contributor.departmentMolecular Oncology Group, The Paterson Institute for Cancer Research, The University of Manchester, Manchester, United Kingdom.en_GB
dc.identifier.journalCancer Discoveryen_GB
html.description.abstractSummary: The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation. Cancer Discov; 3(5); 487-90. ©2013 AACR.


This item appears in the following Collection(s)

Show simple item record